Little is known about the regulation of 5-hydroxytryptaminelB (5-HT1B) receptors, a putative terminal autoreceptor in the central nervous system. We studied the regional responses of [ 1 25IJiodocyanopindolol ([ 1 25!]ICYP)-labeled central 5-HT1B sites to chronic treatment with 5-HT agonists and antagonists at a dose of 10 mglkgld IP for 30 consecutive days in the rat. In controls, there were 3.4-fold regional differences in Bmax , with a rank order of brainstem > hippocampus> cortex, striatum> spinal cord, and Kas were slightly lower in striatum and spinal cord. RU 24969 significantly reduced Bmax 23 to 63% in cortex, hippocampus, striatum, brainstem, and spinal cord without a change in Ka except for a 1.7-fold increase in cortex and spinal cord. The 
putative 5-HT1B agonist (m-trifluoromethyl phenylpiperazine (TFMPP), but not [1-(3-chlorophenyl) piperazinel (m-CPP) or the 5-HT1B antagonists pindolol or quipazine, reduced the Bmax of cortical 5-HT1B sites (-16%). Chronic treatment with the 5-HT antagonists methysergide, pindolol, propranolol, ritanserin, metergoline, or methiothepin did not significantly affect striatal Bmax or Kd compared to respective vehicles. The data demonstrate significant changes in maximum number of 5-HT1B receptors in response to chronic agonist but not antagonist treatments at the dose studied. [Neuropsychopharmacology 10:259-264, 1994J basal ganglia region of importance to certain human dyskinesias or movement disorders. 5-HT1B sites may regulate y-aminobutyric acid (GABA) release in stria tum, blocking the GABAB synaptic potential in mid brain dopamine neurons (Johnson et al. 1992) , and cer ebellar Purkinje cells (Maroteaux et al. 1992) . The 5-HT1B receptor is coupled to the inhibition of adenylyl cyclase by the inhibiting G-protein Gi (Bouhelal et al. 1988; Pleus and Bylund 1992) . A marker behavioral correlate of 5-HTlB receptor activation has been pro posed as stimulatory effects on locomotion based on RU 24969 (Green et al. 1984; Oberlander et al. 1986; Pranzatelli et al. 1987) .
Evidence for differential regulation of 5-HT recep tor subtypes in the mammalian eNS is accumulating.
There have been few studies of the regulation of 5-HTlB receptors. Behavioral tolerance has been 0893-133X/94/$7.00 demonstrated in rodents following repeated adminis tration with RU 24969, m-CPP, or CGS 12066B (Sills et al. 1985; De Souza et al. 1986; Oberlander et al. 1987; Frances and Monier 1991) . antagonists (Glennon 1987; Middlemiss 1985) , drugs for which behavioral data are available. However, TFMPP and m-CPP have activity at 5-HT l C sites and RU 24969, TFMPP, m-CPP and quipazine also bind to 5-HT 2 sites (Hoyer et al. 1985) . [ l 25I]ICYP has been used to selectively labe15-HTlB sites in the presence of isoproterenol to suppress binding to j3-adrenoceptors (Offord et al. 1988; Ariani et al. 1989; Pleus and Bylund 1992) .
METHODS

Animals
Male 200 to 250 g Sprague-Dawley rats (Charles River, Wilmington, MA) were housed three to a cage with ac cess to food and water under constant temperature (23°C) and a 12-hour light/12-hour dark cycle.
Drugs
Drug solutions were prepared immediately before use and sonicated to ensure that they were dissolved. For 1994-VOL. 10, NO.4 (Wilmington, DE). Other reagents were obtained from Sigma.
Drug Injections
Rats were injected IP once daily for 30 consecutive days with 10 mg/kg of a single drug or respective vehicle (sa line, 10% ascorbic acid, saline acidifIed with HCl, or 100% propylene glycol). The use of a 10 mg/kg dose was somewhat arbitrary in terms of 5-HTlB receptor afunities but was selected to allow comparison with be havioral studies (Green et al. 1984; Sills et al. 1985; De Souza et al. 1986; Frances and Monier 1991) and with regulation studies of other 5-HT receptors (Larsson et al. 1990; Pranzatelli 1991; Murthy and Pranzatelli 1992; Pranzatelli et al. 1993 ).
Dissections
Rat brains were dissected 24 hours after the last drug injection on a glass petri dish over ice into cortex, hip pocampus, striatum, brainstem (inclusive of midbrain, pons, and medulla), diencephalon (thalamus and hypothalamus), cerebellum. Whole spinal cord was also removed. Tissues were frozen on dry ice and then stored at -70°C until use.
[125I]lCYP Binding Competition experiments were performed in stri ata from rats treated chronically with 5-HT agonists, 
Statistics
Data were analyzed by analysis of variance (ANOV A) using general linear models (PROC GLM) of SAS statistical software (SAS 1988) . Preplanned post hoc comparisons of least square means were made using t-tests (POIFF). 
RESULTS
Regional Comparison of 5-HTIB Binding Sites
Saturation analyses are shown in Figure 1 . Scatchard plots were linear and fIt a single-site model. There were signifIcant regional differences in specifIc binding to There were large regional differences in the maxi mum density of 5-HTIB binding sites in vehicle injected rats (F = 55.31, P = .0001). The rank order of Bmax was brains tern > hippocampus> cortex, stria tum> spinal cord. There were small regional differences in Kd (nmollL) in saline-injected controls: (F = 6.53, P = .002) with the rank order hippocampus, brainstem, cortex> spinal cord, striatum: hippocampus, 0.21 ± 0.02; brainstem, 0.19 ± 0.01; cortex, 0.19 ± 0.01; spi nal cord, 0.14 ± 0.02; and striatum, 0.12 ± 0.02.
Chronic Agonist Injections
Regional studies were performed on brain and spinal cord from rats treated chronically with RU 24969 (Fig.   2 ). SignifIcant reductions in Bmax were found in brain- Data are mean ± SEM of separate experiments performed in dupli cate. Bmax, Kd and nH values were determined using EBDA. All values for nH were not signifIcantly different than 1.0. stem (-46%), spinal cord (-63%), striatum (-35%), cortex (-24%) and hippocampus (-23%). There was a 1.7-fold increase in Kd cortex (p = .0001) and spinal cord (p = .007, t-test).
In a comparison of 5-HT agonists in cortex (Fig. 3) , RU 24969 (-24%) and TFMPP (-16%) reduced Bmax signifIcantly. DOl, a 5-HT2I1c agonist, and m-CPP had no statistically signifIcant effects on binding parameters.
Chronic Antagonist Injections
In cortex, quipazine and pindolol had no statistically signifIcant effects on binding parameters. In striatum (Table I) , propranolol, pindolol, ritanserin, metergo line, and methiothepin also did not have signifIcant effects compared to their respective vehicles.
Competition Studies
In naive rat striatum, the Ki for RU 24969 was 1.9 ± 0.9 nmol/L, and the value for nH was 0.70 ± 0.04. The Ki for 5-HT in saline-treated controls was 9.7 ± 0.2 nmollL, and the value for nH was 0.76 ± 0.03. Striatal receptor occupancy was approximately 19% as determined by EBOA in competition experiments.
Chronic treatment with 5-HT agonists or antago nists had no signifIcant effect on the Ki of 5-HT in stri atum. The values for Ki were 7.3 ± 0.5 nmollL in the chronic RU 24969-treated group, 10 ± 1 nmol/L in the m-CPP-treated group, and 10 ± 1 in the pindolol-treated group.
DISCUSSION
The main fInding of this study was that chronic treat ment with the 5-HT 1B agonist RU 24969 signifIcantly down-regulated 5-HTIB sites in multiple brain regions and spinal cord and that there were signibcant regional differences in the magnitude of down-regulation. A pat tern of 5-HT agonist-induced receptor recognition site down-regulation detectable by regional binding assays has now been shown for 5-HTlC (Pranzatel1i et al. 1993) , 5-HT2 (Pranzatelli 1991), but not 5-HTIA sites (Larsson et al. 1990 ). The behavioral correlate of 5-HTIB receptor down-regulation would appear to be tolerance to the stimulatory effect of RU 24969 on locomotor ac tivity (Oberlander et al. 1987) . Daily injection of mice for 3 days with 5 mg/kg RU 24969 reduced the be havioral effect of RU 24969 and of other 5-HTlB agonists (Frances and Monier 1991) . Even a single dose of RU 24969 in rats decreased subsequent RU 24969-evoked locomotion (Oberlander et al. 1987) .
5-HT antagonist-induced upregulation of 5-HTIB sites was not found at the doses studied. Earlier studies using nonselective 5-HT antagonists had predicted up regulation of 5-HTI receptors, but so far, no 5-HTI sub type has exhibited upregulation after chronic 5-HT antagonist treatment at a 10 mg/kg dose (Pranzatelli 1991; Pranzatelli et al. 1993) . Offord et al. 1988; Hoyer et al. 1985) . The affinity of metergoline and methiothepin should be sufficient to demonstrate trophic effects with chronic administra tion at the dose used. Studies using higher doses will be necessary to explore this issue further. Evidence for metergoline being a partial agonist rather than an an tagonist on 5-HTlDll receptors has been presented re cently (Miller et al. 1992 ).
There are diff erences in the Brnax rank order of 5-HTIB sites we report and that suggested by autora diographic studies. Several explanations are possible. higher than striatum, however, the inclusion of pons medulla in our brainstem piece would be expected to lower the Brnax according to their data. Their studies
were not saturation studies, however.
The lack of effect of chronic treatment with m-CPP compared to TFMPP and RU 24969 on 5-HTlB sites may relate to the 4.3-fold higher affinity of TFMPP and 25-to 100-fold higher affi nity of RU 24969 in the rat (Sills et al. 1984; Hoyer 1988; Offord et al. 1988; Matsumoto et al. 1992) , although there may be other pharmacoki netic differences between drugs. Our binding data sug gest that, at a dose of 10 mg/kg, m-CPP does not act at 5-HTIB receptors in the rat, whereas this dose in the same rats does down-regulate 5-HTlC sites in spinal cord (Pranzatelli et al. 1993 ) but not 5-HTIA sites in brainstem (Murthy and Pranzatelli 1992) . It has been suggested that although indole 5-HTlB agonists stimu late hyperlocomotion by stimulating presynaptic 5-HTlB sites, phenylpiperazine 5-HTlB agonists exert the opposite behavioral effect by acting postsynaptically (Oberlander et al. 1987) . However, pharmacological studies of the hypo activity induced by m-CPP and TFMPP have associated it with 5-HTlC receptors in stead of 5-HTIB receptors (Kennett and Curzon 1988; Lucki et al. 1989 ).
